Telomere Parameters in Patients With Nonalcoholic Fatty Liver

• Conditions: FATTY LIVER; NO MALIGNANCY; NO DECOMPENSATED ILLNESS

• Registration Number: NCT01694342
• Lead Sponsor: Meir Medical Center

Brief Summary

Telomerase, through its regulatory function on telomere length may play an important role in immune function, cellular replicative life span, and carcinogenesis. Non-alcoholic fatty liver disease (NAFLD) is considered a benign condition, but in some cases, it may progress to cirrhosis and hepatocellular carcinoma. The risk factors for that evolution are not fully understood.

Our group showed in a previous study, that hTERT mRNA expression is lower in peripheral lymphocytes of patients with fatty liver, compared to healthy controls. This finding could explain the telomere shortening found previously in these patients by our group \[20\] and others \[21\]. Furthermore, we found higher rates of TC in these patients, probably due to an attempt to counteract the shortening of the telomeres and to stabilize them. This is through a different mechanism that is not telomerase-mediated.

Telomere capture is considered an alternative way to maintain telomere length and chromosomal stability \[3\]. It is a more common mechanism for chromosome stabilization and repair, in contrast to the telomerase-mediated process of chromosome healing and elongation This study aimed to evaluate mechanisms of telomere homeostasis like telomere shortening, telomerase activity, telomere capture and aneuploidy in patients with NAFLD in order to explain previous findings of telomere shortening in these patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2012-07
• Study Start: 2012-09
• Study First Submitted: 2012-09-23
• Study First Submitted QC: 2012-09-26
• Last Update Submitted: 2012-09-26
• Study First Posted: 2012-09-27
• Last Update Posted: 2012-09-27

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• age over 18
• diagnosis of fatty liver

Exclusion Criteria

• no malignancy
• no eligible to sign the consent paper

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Meir Hospital; 🇮🇱 Kefar Saba, Israel